PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg

PepGen Inc.

2025-Q1 EPS reported -$0.92

Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.
Cash and marketable securities $97.8M as of March 31, 2025; runway at least 12 months.
Positive DM1 data: mean splicing correction of 29.1% 28 days after single 10 mg/kg dose of PGN-EDODM1.
CONNECT1-EDO51 10 mg/kg dystrophin data expected Q3 2025; CONNECT2 trial voluntarily paused.
Board added Lisa Wyman and Mitchell H. Finer, PhD in March 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.